BiotechTube

Decitabine + Pegylated Interferon Alpha-2b

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma

Conditions

Melanoma

Trial Timeline

Sep 2, 2008 → May 1, 2015

NCT ID
NCT00791271

About Decitabine + Pegylated Interferon Alpha-2b

Decitabine + Pegylated Interferon Alpha-2b is a phase 1 stage product being developed by Eisai for Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00791271. Target conditions include Melanoma.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma were approved

Approved (4) Terminated (2) Active (14)
✅dabrafenib + trametinibNovartisApproved
✅ZelborafRocheApproved
✅Nivolumab + RelatlimabBristol Myers SquibbApproved
✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved
❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00791271Phase 1Terminated

Competing Products

20 competing products in Melanoma

See all competitors
ProductCompanyStageHype Score
mRNA-4157 + PembrolizumabMerckPhase 2
39
AVT32-DRL_PB + KeytrudaDr. Reddy's LaboratoriesPhase 1
33
Binimetinib Oral TabletBiotrialPhase 1
15
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
32
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
23
FYB206 + KeytrudaFormycon AGPhase 1
23
PLX3397Daiichi SankyoPre-clinical
26
PLX3397 + PembrolizumabDaiichi SankyoPhase 1/2
24
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
DS-8273a + NivolumabDaiichi SankyoPhase 1
29
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
42
CP-461Astellas PharmaPhase 2
27
YM155Astellas PharmaPhase 2
35
YM155 + DocetaxelAstellas PharmaPhase 2
35
Denileukin diftitoxEisaiPhase 2
35
E7080EisaiPhase 1
29
lenvatinib + pembrolizumabEisaiPhase 2
35
MORAb-004 (monoclonal antibody)EisaiPhase 2
35